| Expression pattern: |
UP |
| Associated gene: |
PLCL2, CDKN1B |
| Associated microRNA: |
miR-377 |
| Biological function: |
confers/promotes enzalutamide resistance in vitro |
| Molecular mechanism: |
possible ceRNA networks (hypothesized; not fully delineated) |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (other); drug resistance (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Sanger Sequencing; Transfection; ELISA; Clinical Sample Validation; RT-ddPCR |
| Clinical significance: |
Plasma expression showed a trend mirroring PSA-defined disease activity, but not statistically significant; limited utility as liquid-based predictive biomarker in this cohort |
| Description: |
hsa_circ_0001275 is up-regulated in enzalutamide-resistant LNCaP clones and its stable overexpression increases enzalutamide resistance in vitro. Plasma levels show a PSA-paralleling trend in an MCRPC clinical trial cohort but without statistical significance; mechanism is suggested to involve ceRNA networks but not proven. |
| Confidence score: |
0.6875 |